J&amp;J to buy Guidant for $25.4bn
605466
Johnson &amp; Johnson last night struck a deal to acquire Guidant, the US cardiac treatment group for $25.4bn, in a move that will give it access to one of the fastest growing areas in health care.
95065
Credit Suisse First Boston maintained &quot;neutral&quot; ratings on Guidant (nyse: GDT - news - people ) and Johnson &amp; Johnson (nyse: JNJ - news - people ), saying a near-term acquisition of the former by the latter values Guidant at $76.
731068
Johnson & Johnson will acquire the cardiac device manufacturer for $25.4 billion. The acquisition is the largest business deal in J&J's 118-year history
179502
Shares of medical device maker Guidant  Corp.GDT.N jumped on Tuesday after a report saying the  company was in advanced talks to be acquired by health products  maker Johnson & Johnson JNJ.N for more than $24 billion.
85267
Johnson &amp; Johnson agreed to acquire Guidant Corp. for $25.4 billion, adding electrical devices for treating heart disease to a lineup of thousands of health products including Band-Aids and cardiac stents.
351599
NEW YORK -- Johnson &amp; Johnson will acquire Guidant Corp., one of the world&#39;s leading makers of cardiac devices, for about $25.4 billion in cash and stock.
218540
Johnson &amp; Johnson is in advanced talks to acquire Guidant Corp. for more than $24 billion, according to a New York Times report.
281234
TOKYO -- Japan Tobacco Inc. announced plans Friday to buy Britain's Gallaher Group PLC for 2.25 trillion yen ($19.1 billion) in reportedly the largest-ever corporate acquisition by a Japanese company.
336391
U.S. blue chips closed slightly higher  on Thursday, helped by Johnson & Johnson Inc.'s JNJ.N $25  billion deal to buy Guidant Corp. GDT.N, but the broader  market fell, with Goldman Sachs Group Inc. GS.N dragging the  S&P 500 lower after posting quarterly revenues that  disappointed Wall Street.
584724
Johnson &amp; Johnson (JNJ), the drug and health care products company, is reportedly in advanced negotiations to buy Guidant (GDT), a leading maker of devices to treat heart and circulatory illnesses, for more than $24 billion.
6925
Johnson &amp; Johnson (JNJ.N: Quote, Profile, Research) on Thursday said it does not see any significant antitrust roadblocks getting in the way of its $25.4 billion acquisition of medical device maker Guidant Corp.
312138
U.S. stocks were little changed on  Tuesday, with lower oil prices helping support markets, but  Johnson & Johnson JNJ.N dragged on the Dow following a report  of a possible $24 billion takeover of cardiovascular device  maker Guidant Corp. GDT.N.
466964
NEW YORK Johnson &amp; Johnson is in advanced negotiations to acquire Guidant, one of the largest US makers of devices to treat heart and circulatory illnesses, according to executives close to the talks.
373656
Johnson &amp; Johnson said late Wednesday that it will buy Guidant Corp. for $23.9 billion in a cash-and-stock deal that had been rumored for weeks.
5729
Health care products giant Johnson &amp; Johnson&#39;s $25.4 billion acquisition of Guidant Corp. could face a tough review from regulators because of their competition in the coronary stent market, analysts say.
565121
Johnson & Johnson, the pharmaceutical and health care giant, is near a deal to buy Guidant, one of the nation's largest makers of devices to treat heart and circulatory illnesses.
177578
Even as the ink dries on Johnson &amp; Johnson&#39;s agreement to buy Guidant Corp. for $25.4 billion, it remains on the hunt for other companies that could bolster